NU 6027
|
- ₹16670.01
- Product name: NU 6027
- CAS: 220036-08-8
- MF: C11H17N5O2
- MW: 251.29
- EINECS:
- MDL Number:MFCD05664735
- Synonyms:ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem;NU6027;NU-6027;NU 6027;2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso-;ATR/CDK Inhibitor, NU6027 ;2,6-DiaMino-4-(cyclohexylMethoxy)-5-nitrosopyriMidine;6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine;NU 6027 USP/EP/BP;inhibit,Ataxia telangiectasia mutated,Cyclin dependent kinase,ATM/ATR,NU 6027,cytotoxicity,NU6027,Inhibitor,NU-6027,CDK2,cisplatin,hydroxyurea,ATR,CDK1,CDK,ATM and RAD3 related,cancer
1 prices
Selected condition：
Brand
- Sigma-Aldrich(India)
Package
- 10MG
- ManufacturerSigma-Aldrich(India)
- Product number189299
- Product descriptionATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem The ATR/CDK Inhibitor, NU6027, also referenced under CAS 220036-08-8, controls the biological activity of ATR/CDK. This small molecule/inhibitor is pr
- Packaging10MG
- Price₹16670.01
- Updated2022-06-14
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | 189299 | ATR/CDK Inhibitor, NU6027 - CAS 220036-08-8 - Calbiochem The ATR/CDK Inhibitor, NU6027, also referenced under CAS 220036-08-8, controls the biological activity of ATR/CDK. This small molecule/inhibitor is pr | 10MG | ₹16670.01 | 2022-06-14 | Buy |
Properties
Melting point :252.5-253.7 °C(lit.)
Boiling point :549.2±60.0 °C(Predicted)
Density :1.53±0.1 g/cm3(Predicted)
storage temp. :2-8°C
solubility :DMSO: 15 mg/mL
pka :2.52±0.10(Predicted)
form :Reddish-purple powder
color :lavender
Boiling point :549.2±60.0 °C(Predicted)
Density :1.53±0.1 g/cm3(Predicted)
storage temp. :2-8°C
solubility :DMSO: 15 mg/mL
pka :2.52±0.10(Predicted)
form :Reddish-purple powder
color :lavender
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|
Description
Cyclin-dependent kinases (CDKs) play a key role in regulating cell division by phosphorylating distinct substrates in different phases of the cell cycle. Cell cycle deregulation in many cancers often results from altered CDK activity. Thus, CDKs are potential pharmacological targets for anticancer agents. NU 6027 inhibits both CDK1 and CDK2 with IC50 values of 2.9 and 2.2 μM, respectively. It has been shown to inhibit cellular ataxia telangiectasia mutated and Rad3-realted kinase activity (IC50 = 6.7 μM) and impair G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin.More related product prices
SU 9516